{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:54:08Z","timestamp":1793091248905,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"37","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Defense Advanced Research Projects Administration"},{"DOI":"10.13039\/100000183","name":"U.S. Army Research Office","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000183","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.vaccine.2011.05.047","type":"journal-article","created":{"date-parts":[[2011,6,8]],"date-time":"2011-06-08T14:27:59Z","timestamp":1307543279000},"page":"6313-6320","source":"Crossref","is-referenced-by-count":86,"title":["Marked enhancement of the immune response to BioThrax\u00ae (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers"],"prefix":"10.1016","volume":"29","author":[{"given":"Dianna","family":"Rynkiewicz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Thomas","family":"Waytes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lallan","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"DeMuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Ransom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary S.","family":"Nabors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl J.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2011.05.047_bib0005","series-title":"Vaccines","first-page":"111","article-title":"Anthrax vaccine","author":"Brachman","year":"2008"},{"issue":"November (4)","key":"10.1016\/j.vaccine.2011.05.047_bib0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8561(03)00093-6","article-title":"Anthrax vaccine: a review","volume":"23","author":"Grabenstein","year":"2003","journal-title":"Immunol Allergy Clin N Am"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.05.047_bib0015","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1128\/IAI.69.5.2888-2893.2001","article-title":"Search for correlates of protective immunity conferred by anthrax vaccine","volume":"69","author":"Reuveny","year":"2001","journal-title":"Infect Immun"},{"issue":"October (13)","key":"10.1016\/j.vaccine.2011.05.047_bib0020","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jama.300.13.1532","article-title":"Effects of a reduced dose schedule and intramuscular administration of Anthrax Vaccine Adsorbed on immunogenicity and safety at 7 months","volume":"300","author":"Marano","year":"2008","journal-title":"JAMA"},{"issue":"RR-6","key":"10.1016\/j.vaccine.2011.05.047_bib0025","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright","year":"2010","journal-title":"Morb Mortal Wkly Rep"},{"issue":"9","key":"10.1016\/j.vaccine.2011.05.047_bib0030","first-page":"E3","article-title":"Bichat guidelines for the clinical management of anthrax and bioterrorism-related anthrax","volume":"15","author":"Bossi","year":"2004","journal-title":"Euro Surveill"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2011.05.047_bib0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"issue":"Febuary (4)","key":"10.1016\/j.vaccine.2011.05.047_bib0040","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005","volume":"144","author":"Holty","year":"2006","journal-title":"Ann Intern Med"},{"issue":"May (18)","key":"10.1016\/j.vaccine.2011.05.047_bib0045","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.281.18.1735","article-title":"Anthrax as a biological weapon: medical and public health management","volume":"281","author":"Inglesby","year":"1999","journal-title":"JAMA"},{"issue":"February (7)","key":"10.1016\/j.vaccine.2011.05.047_bib0050","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/jama.287.7.863","article-title":"Fatal inhalational anthrax in a 94-year-old Connecticut woman","volume":"287","author":"Barakat","year":"2002","journal-title":"JAMA"},{"issue":"February (6)","key":"10.1016\/j.vaccine.2011.05.047_bib0055","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pds.1085","article-title":"An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program","volume":"14","author":"Martin","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"December (50)","key":"10.1016\/j.vaccine.2011.05.047_bib0060","first-page":"1142","article-title":"Additional options for preventive treatment for exposed persons to inhalational anthrax","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"Morb Mortal Wkly Rep"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2011.05.047_bib0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S0022172400044272","article-title":"Observations on the prophylaxis of experimental pulmonary anthrax in the monkey","volume":"54","author":"Henderson","year":"1956","journal-title":"J Hyg (Lond)"},{"issue":"May (5)","key":"10.1016\/j.vaccine.2011.05.047_bib0070","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/infdis\/167.5.1239","article-title":"Postexposure prophylaxis against experimental inhalation anthrax","volume":"167","author":"Friedlander","year":"1993","journal-title":"J Infect Dis"},{"issue":"November (11)","key":"10.1016\/j.vaccine.2011.05.047_bib0075","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1128\/AAC.00090-06","article-title":"Pharmacokinetic considerations and efficacy of levofloxacin in an inhalational anthrax (postexposure) rhesus monkey model","volume":"50","author":"Kao","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.05.047_bib0080","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3201\/eid0810.020349","article-title":"Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence","volume":"8","author":"Shepard","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.05.047_bib0085","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.3201\/eid0810.020331","article-title":"Adherence to antimicrobial inhalational anthrax prophylaxis among postal workers, Washington, DC, 2001","volume":"8","author":"Jefferds","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"February (2)","key":"10.1016\/j.vaccine.2011.05.047_bib0090","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkh016","article-title":"In vitro susceptibility of Bacillus anthracis to various antibacterial agents and their time-kill activity","volume":"53","author":"Athamna","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.vaccine.2011.05.047_bib0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0924-8579(01)00464-2","article-title":"In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones","volume":"18","author":"Brook","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"10.1016\/j.vaccine.2011.05.047_bib0100","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/jac\/dkh258","article-title":"Selection of Bacillus anthracis isolates resistant to antibiotics","volume":"54","author":"Athamna","year":"2004","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"10.1016\/j.vaccine.2011.05.047_bib0105","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/jac\/dkh294","article-title":"Type II topoisomerase mutations in Bacillus anthracis associated with high-level fluoroquinolone resistance","volume":"54","author":"Bast","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.vaccine.2011.05.047_bib0110","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1146\/annurev.immunol.20.100301.064842","article-title":"CpG motifs in bacterial DNA and their immune effects","volume":"20","author":"Krieg","year":"2002","journal-title":"Annu Rev Immunol"},{"issue":"June (6)","key":"10.1016\/j.vaccine.2011.05.047_bib0115","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nrd2059","article-title":"Therapeutic potential of Toll-like receptor 9 activation","volume":"5","author":"Krieg","year":"2006","journal-title":"Nat Rev Drug Discov"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2011.05.047_bib0120","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/08830180600743057","article-title":"Adjuvant activity of CpG oligodeoxynucleotides","volume":"25","author":"Klinman","year":"2006","journal-title":"Int Rev Immunol"},{"issue":"5","key":"10.1016\/j.vaccine.2011.05.047_bib0125","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2165\/00126839-200607050-00004","article-title":"CpG 7909: PF 3512676, PF-3512676","volume":"7","year":"2006","journal-title":"Drugs R D"},{"issue":"July (21\u201322)","key":"10.1016\/j.vaccine.2011.05.047_bib0130","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1016\/j.vaccine.2003.12.020","article-title":"CpG oligonucleotides improve the protective immune response induced by the anthrax vaccination of rhesus macaques","volume":"22","author":"Klinman","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.05.047_bib0135","series-title":"ASM biodefense research meeting","article-title":"The immunogenicity and protective capacity of BioThrax\u00ae are significantly enhanced by CPG 7909","author":"Gu","year":"2006"},{"issue":"January (3)","key":"10.1016\/j.vaccine.2011.05.047_bib0140","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.vaccine.2006.07.056","article-title":"Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109","volume":"25","author":"Gu","year":"2007","journal-title":"Vaccine"},{"issue":"June (3)","key":"10.1016\/j.vaccine.2011.05.047_bib0145","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1586\/14760584.5.3.365","article-title":"CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine","volume":"5","author":"Klinman","year":"2006","journal-title":"Expert Rev Vaccines"},{"issue":"October (12\u201313)","key":"10.1016\/j.vaccine.2011.05.047_bib0150","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/j.micinf.2007.08.002","article-title":"Systemic but not mucosal immunity induced by AVA prevents inhalational anthrax","volume":"9","author":"Klinman","year":"2007","journal-title":"Microbes Infect"},{"issue":"November (4)","key":"10.1016\/j.vaccine.2011.05.047_bib0155","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8561(03)00093-6","article-title":"Anthrax vaccine: a review","volume":"23","author":"Grabenstein","year":"2003","journal-title":"Immunol Allergy Clin N Am"},{"issue":"October (10)","key":"10.1016\/j.vaccine.2011.05.047_bib0160","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3201\/eid0810.020380","article-title":"Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen","volume":"8","author":"Quinn","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"March (1)","key":"10.1016\/j.vaccine.2011.05.047_bib0165","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.biologicals.2003.09.003","article-title":"Validation of the anthrax lethal toxin neutralization assay","volume":"32","author":"Hering","year":"2004","journal-title":"Biologicals"},{"issue":"April (1\u20132)","key":"10.1016\/j.vaccine.2011.05.047_bib0170","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jim.2008.01.007","article-title":"Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization","volume":"333","author":"Li","year":"2008","journal-title":"J Immunol Methods"},{"issue":"September (5)","key":"10.1016\/j.vaccine.2011.05.047_bib0175","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CDLI.11.5.919-923.2004","article-title":"Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum","volume":"11","author":"Semenova","year":"2004","journal-title":"Clin Diagn Lab Immunol"},{"issue":"January (9\u201310)","key":"10.1016\/j.vaccine.2011.05.047_bib0180","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/S0264-410X(01)00462-5","article-title":"Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans","volume":"20","author":"Pittman","year":"2002","journal-title":"Vaccine"},{"issue":"December (50)","key":"10.1016\/j.vaccine.2011.05.047_bib0185","first-page":"1142","article-title":"Additional options for preventive treatment for exposed persons to inhalational anthrax","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","journal-title":"Morb Mortal Wkly Rep"},{"issue":"November (6)","key":"10.1016\/j.vaccine.2011.05.047_bib0190","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10875-004-6244-3","article-title":"CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I\/II study","volume":"24","author":"Cooper","year":"2004","journal-title":"J Clin Immunol"},{"issue":"January (3\u20134)","key":"10.1016\/j.vaccine.2011.05.047_bib0195","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.vaccine.2003.07.004","article-title":"Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine","volume":"22","author":"Little","year":"2004","journal-title":"Vaccine"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.05.047_bib0200","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1128\/IAI.74.1.394-398.2006","article-title":"Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits","volume":"74","author":"Weiss","year":"2006","journal-title":"Infect Immun"},{"issue":"September (32)","key":"10.1016\/j.vaccine.2011.05.047_bib0205","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1016\/S0264-410X(01)00234-1","article-title":"In vitro correlate of immunity in a rabbit model of inhalational anthrax","volume":"19","author":"Pitt","year":"2001","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2011.05.047_bib0210","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1016\/j.vaccine.2009.01.094","article-title":"A single-dose combination therapy that both prevents and treats anthrax infection","volume":"27","author":"Klinman","year":"2009","journal-title":"Vaccine"},{"issue":"October (8)","key":"10.1016\/j.vaccine.2011.05.047_bib0215","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.4049\/jimmunol.181.8.5785","article-title":"Effect of CpG oligonucleotides on vaccine-induced B cell memory","volume":"181","author":"Tross","year":"2008","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2011.05.047_bib0220","unstructured":"The anthrax vaccine: is it safe? Does 658 it work? Washington, DC: Institute of Medicine; 2002."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11007675?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11007675?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T19:43:49Z","timestamp":1592595829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11007675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":44,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0264410X11007675"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.05.047","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}